They also found that a neutralizing antibody against fractalkine might significantly reduce the adhesion of prostate cancer cells to human bone marrow endothelial cells, suggesting the important role of fractalkine in this process (13). The gene discussed is CX3CL1; the disease is prostate carcinoma.